Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.

Finkelstein JS, Wyland JJ, Lee H, Neer RM

The Journal of clinical endocrinology and metabolism17 Feb 2010Cited by 198 (Europe PMC)

PMID20164296PMCIDPMC2853981DOI10.1210/jc.2009-1703PepBankPUB-20164296

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with low BMD, teriparatide alone increased DXA spine BMD more than alendronate alone.
In plain wordsIn postmenopausal women, teriparatide alone increased spine bone density more than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDXA spine BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
Spine BMD increase
18%
teriparatide alone
Spine BMD increase
7%
alendronate alone
Source sentences
Summary
DXA spine BMD increased more in women treated with teriparatide alone than with alendronate alone (18 +/- 11 vs. 7 +/- 4%; P < 0.001) or both (18+/-11 vs. 12 +/- 9%; P = 0.045).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
Report a problemFND-2016429601
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with low BMD, teriparatide alone increased femoral neck BMD more than alendronate alone.
In plain wordsIn postmenopausal women, teriparatide alone increased femoral neck bone density more than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
Femoral neck BMD increase
11%
teriparatide alone
Femoral neck BMD increase
4%
alendronate alone
Source sentences
Summary
Similarly, femoral neck BMD increased more in women treated with teriparatide alone than with alendronate alone (11 +/- 5 vs. 4 +/- 4%; P < 0.001) or both (11 +/- 5 vs. 3 +/- 5%; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
Report a problemFND-2016429603
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide alone increased QCT spine BMD more than alendronate alone.
In plain wordsIn postmenopausal women, spine bone density measured by CT increased more with teriparatide alone than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseQCT spine BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
QCT spine BMD increase
61%
teriparatide alone
QCT spine BMD increase
1%
alendronate alone
Source sentences
Summary
Quantitative computed tomography spine BMD increased 1 +/- 7, 61 +/- 31, and 24 +/- 24% in groups 1, 2, and 3 (P < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
Report a problemFND-2016429605
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to alendronate increased QCT spine BMD more than alendronate alone.
In plain wordsIn postmenopausal women, teriparatide plus alendronate increased spine bone density measured by CT more than alendronate alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombination QCT spine BMD versus alendronate
Study
n: not reported in source
Comparator
Alendronate alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
QCT spine BMD increase
24%
combination
QCT spine BMD increase
1%
alendronate alone
Source sentences
Summary
Quantitative computed tomography spine BMD increased 1 +/- 7, 61 +/- 31, and 24 +/- 24% in groups 1, 2, and 3 (P < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
Report a problemFND-2016429607

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with low BMD, teriparatide alone increased DXA spine BMD more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, teriparatide alone increased spine bone density more than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDXA spine BMD versus combination
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD increase
18%
teriparatide alone
Spine BMD increase
12%
combination
Source sentences
Summary
DXA spine BMD increased more in women treated with teriparatide alone than with alendronate alone (18 +/- 11 vs. 7 +/- 4%; P < 0.001) or both (18+/-11 vs. 12 +/- 9%; P = 0.045).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429602
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with low BMD, teriparatide alone increased femoral neck BMD more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, teriparatide alone increased femoral neck bone density more than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD versus combination
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD increase
11%
teriparatide alone
Femoral neck BMD increase
3%
combination
Source sentences
Summary
Similarly, femoral neck BMD increased more in women treated with teriparatide alone than with alendronate alone (11 +/- 5 vs. 4 +/- 4%; P < 0.001) or both (11 +/- 5 vs. 3 +/- 5%; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429604
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide alone increased QCT spine BMD more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, spine bone density measured by CT increased more with teriparatide alone than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseQCT spine BMD versus combination
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Measurements
QCT spine BMD increase
61%
teriparatide alone
QCT spine BMD increase
24%
combination
Source sentences
Summary
Quantitative computed tomography spine BMD increased 1 +/- 7, 61 +/- 31, and 24 +/- 24% in groups 1, 2, and 3 (P < 0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429606
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide alone increased serum osteocalcin more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, teriparatide alone increased osteocalcin more than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum osteocalcin
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum osteocalcin, N-terminal propeptide of type 1 collagen, and cross-linked N-telopeptides of type I collagen increased more with teriparatide alone than with both (P < 0.001 for each marker).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429608
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide alone increased type 1 collagen N-terminal propeptide more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, teriparatide alone increased the collagen formation marker more than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseType 1 collagen N-terminal propeptide
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum osteocalcin, N-terminal propeptide of type 1 collagen, and cross-linked N-telopeptides of type I collagen increased more with teriparatide alone than with both (P < 0.001 for each marker).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429609
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women, teriparatide alone increased cross-linked N-telopeptides of type I collagen more than teriparatide plus alendronate.
In plain wordsIn postmenopausal women, teriparatide alone increased the collagen breakdown marker more than teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseType I collagen cross-linked N-telopeptides
Study
n: not reported in source
Comparator
Teriparatide plus alendronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum osteocalcin, N-terminal propeptide of type 1 collagen, and cross-linked N-telopeptides of type I collagen increased more with teriparatide alone than with both (P < 0.001 for each marker).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized controlled trial conducted in a single university hospital.Patients and interventionWe randomized 93 postmenopausal women with low bone mineral density (BMD) to alendronate 10 mg daily (group 1), teriparatide 40 microg sc daily (group 2), or both (group 3) for 30 month…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2016429610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01750086

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Massachusetts General Hospitaln = 27Jan 2013 to Aug 2014

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 27 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.